Mika Naganawa, PhD
Research Scientist in Radiology and Biomedical ImagingDownloadHi-Res Photo
Cards
Appointments
Contact Info
About
Copy Link
Titles
Research Scientist in Radiology and Biomedical Imaging
Appointments
Radiology & Biomedical Imaging
Research ScientistPrimary
Other Departments & Organizations
Education & Training
- JSPS Research Fellow PD
- National Institute of Radiological Sciences (2008)
- JSPS Research Fellow PD
- Tokyo Metropolitan Institute of Gerontology (2007)
- COE Program Researcher
- Nara Institute of Science and Technology (2005)
- PhD
- University of Tokyo, Frontier Sciences (2004)
- MS
- University of Tokyo, Frontier Sciences (2001)
- BE
- University of Tokyo, Engineering (1999)
Research
Copy Link
Overview
Medical Research Interests
Biomedical Engineering; Dementia; Kinetics; Nuclear Medicine; Pharmacokinetics; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Opioid, kappa; Substance-Related Disorders
Public Health Interests
Aging; Mental Health; Modeling; Substance Use, Addiction; Statistical Computing
ORCID
0000-0002-4408-2621
Research at a Glance
Yale Co-Authors
Frequent collaborators of Mika Naganawa's published research.
Publications Timeline
A big-picture view of Mika Naganawa's research output by year.
Research Interests
Research topics Mika Naganawa is interested in exploring.
Richard Carson, PhD
Nabeel Nabulsi, PhD
Takuya Toyonaga, MD, PhD
Jean-Dominique Gallezot, PhD
Ming-Kai Chen, MD, PhD
Shannan Henry
107Publications
4,919Citations
Positron-Emission Tomography
Radiopharmaceuticals
Kinetics
Receptors, Opioid, kappa
Pharmacokinetics
Nuclear Medicine
Publications
2025
Neural Signatures of Bipolar Disorder and Psychotropic Medication Effects: A Multimodal PET–MRI Study
Asch R, Fan S, Cool R, Boster S, DellaGioia N, Naganawa M, Nabulsi N, Lacadie C, Pietrzak R, Esterlis I. Neural Signatures of Bipolar Disorder and Psychotropic Medication Effects: A Multimodal PET–MRI Study. Biological Psychiatry 2025 PMID: 41325959, DOI: 10.1016/j.biopsych.2025.11.018.Peer-Reviewed Original ResearchConceptsGray matter volumeBipolar disorderMedication effectsNeural signaturesPsychotropic medicationsFronto-limbic brain regionsAssociated with greater impulsivityPositron emission tomographyC]UCB-J positron emission tomographyNeurobiology of bipolar disorderSynaptic densitySynaptic vesicle glycoprotein 2AIllness-related changesMatter volumeSV2A densityBD individualsBrain regionsFunctional MRIBrain structuresGroup differencesSynaptic deficitsNeuroimaging findingsPET-MRI studiesMedical statusIn vivo evidenceMeasuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual‐Tracer Positron Emission Tomography Imaging Study
Sadabad F, Volpi T, Honhar P, Tinaz S, Dias M, Toyonaga T, Naganawa M, Gallezot J, Yang Y, Ibrahim W, Pittman B, Cayir S, Radhakrishnan R, Angarita G, Holmes S, Comley R, Carson R, Finnema S, Matuskey D. Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual‐Tracer Positron Emission Tomography Imaging Study. Movement Disorders 2025, 40: 2678-2687. PMID: 41040062, DOI: 10.1002/mds.70041.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsC-UCB-JDopamine transporterHealthy controlsVentral striatumDisease stageSubstantia nigraSynaptic densityParkinson's diseaseDopamine transporter availabilityPositron emission tomography imaging studiesSynaptic vesicle glycoprotein 2AAssessment of synaptic densityDopaminergic denervationBetween-group differencesTransporter availabilityBinding potentialNigrostriatal regionDisease durationDual-tracerImaging studiesPatientsPET imagingPresynaptic degenerationPD patientsDopaminePET imaging evidence of HDAC6 suppression in the amygdala across species in PTSD
Bonomi R, Naganawa M, McRiley D, Toyonaga T, LeVasseur B, Duman C, Huang Y, Matuskey D, Carson R, Pietrzak R, Girgenti M, Cosgrove K. PET imaging evidence of HDAC6 suppression in the amygdala across species in PTSD. Molecular Psychiatry 2025, 30: 5381-5388. PMID: 40753309, DOI: 10.1038/s41380-025-03124-8.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPosttraumatic stress disorderPathophysiology of posttraumatic stress disorderNon-trauma-exposed controlsAmygdala of individualsProlonged stress modelBrain imaging studiesStress disorderRodent findingsNuclear translocation of glucocorticoid receptorTranslocation of glucocorticoid receptorHuman findingsTranslational findingsCortisol signalingAmygdalaGlucocorticoid receptorComplex disorderImaging studiesDisordersLongitudinal analysisStress modelHistone deacetylase 6Pharmacological targetsHistone deacetylasesFindingsNuclear translocationAssessment of test-retest reproducibility by [18F]Bavarostat for PET imaging of HDAC6
Naganawa M, Zheng M, Gallezot J, Bonomi R, Gu J, Gao H, Jacutin-Porte S, Nabulsi N, Koole M, Van Laere K, Matuskey D, Huang Y, Carson R. Assessment of test-retest reproducibility by [18F]Bavarostat for PET imaging of HDAC6. EJNMMI Research 2025, 15: 76. PMID: 40542929, PMCID: PMC12182542, DOI: 10.1186/s13550-025-01268-w.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAbsolute test-retest variabilityMultilinear analysis-1Time-activity curvesTest-retest variabilityRegional time-activity curvesTest-retest reproducibilityVT valuesTwo-tissue compartment modelEffect of scan durationInterscan intervalRegional VT valuesTest-retest scansScan durationArterial blood samplesBrain bindingOne-tissuePET/CT scannerCentrum semiovaleDistribution volumePET imagingAnalysis-1Blood samplesTherapeutic targetBrain regionsHDAC6 inhibitors612. Early Evidence for Lower HDAC6 Levels in the Amygdala of Individuals With AUD
Bonomi R, Naganawa M, William R, Zakiniaeiz Y, Huang Y, Matuskey D, Cosgrove K. 612. Early Evidence for Lower HDAC6 Levels in the Amygdala of Individuals With AUD. Biological Psychiatry 2025, 97: s350-s351. DOI: 10.1016/j.biopsych.2025.02.851.Peer-Reviewed Original ResearchAltmetricVenous blood sampling for less invasive in vivo quantification of synaptic density with constant infusion of [18F]SynVesT-1 and PET
Asch R, Naganawa M, Moisieienko K, Weed M, Kapinos M, Zheng M, Hillmer A, Carson R, Pietrzak R, Esterlis I. Venous blood sampling for less invasive in vivo quantification of synaptic density with constant infusion of [18F]SynVesT-1 and PET. EJNMMI Research 2025, 15: 8. PMID: 39900828, PMCID: PMC11790547, DOI: 10.1186/s13550-025-01200-2.Peer-Reviewed Original Research
2024
11C-UCB-J PET imaging is consistent with lower synaptic density in autistic adults
Matuskey D, Yang Y, Naganawa M, Koohsari S, Toyonaga T, Gravel P, Pittman B, Torres K, Pisani L, Finn C, Cramer-Benjamin S, Herman N, Rosenthal L, Franke C, Walicki B, Esterlis I, Skosnik P, Radhakrishnan R, Wolf J, Nabulsi N, Ropchan J, Huang Y, Carson R, Naples A, McPartland J. 11C-UCB-J PET imaging is consistent with lower synaptic density in autistic adults. Molecular Psychiatry 2024, 30: 1610-1616. PMID: 39367053, DOI: 10.1038/s41380-024-02776-2.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPositron emission tomographySynaptic densityAutistic adultsBrain regionsAutistic featuresClinical phenotype of autismNon-autistic participantsPhenotype of autismNon-autistic individualsRelationship to clinical characteristicsSynaptic vesicle glycoprotein 2AAssociated with clinical measuresPost-mortem studiesPositron emission tomography scanPrefrontal cortexClinician ratingsAutism groupNeural basisBrain areasNeural processesBetween-group differencesVolumetric differencesBinding potentialDensity of synapsesAutismValidation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [11C]UCB-J PET
Young J, O’Dell R, Naganawa M, Toyonaga T, Chen M, Nabulsi N, Huang Y, Cooper E, Miller A, Lam J, Bates K, Ruan A, Nelsen K, Salardini E, Carson R, van Dyck C, Mecca A. Validation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [11C]UCB-J PET. Journal Of Nuclear Medicine 2024, 65: jnumed.124.267419. PMID: 39299782, PMCID: PMC11533916, DOI: 10.2967/jnumed.124.267419.Peer-Reviewed Original ResearchCitationsAltmetricConceptsDistribution volume ratioSUV ratioSynaptic densityEffect sizeAlzheimer's diseaseLongitudinal study of Alzheimer's diseaseMethods: ParticipantsLongitudinal studyMeasure synaptic densityAD participantsStudy of Alzheimer's diseaseNormal cognitionReference regionOlder adultsMulticenterDensity alterationsClinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights
Honhar P, Sadabad F, Tinaz S, Gallezot J, Dias M, Naganawa M, Yang Y, Henry S, Hillmer A, Gao H, Najafzadeh S, Comley R, Nabulsi N, Huang Y, Finnema S, Carson R, Matuskey D. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights. Brain Communications 2024, 6: fcae345. PMID: 39429243, PMCID: PMC11487911, DOI: 10.1093/braincomms/fcae345.Peer-Reviewed Original ResearchCitationsConceptsDAT availabilityMotor severitySubstantia nigraDopamine transporter availabilityClinical trials of Parkinson's diseaseParkinson's diseaseLongitudinal studyTracking longitudinal changesClinical correlatesVentral striatumTransporter availabilityNigrostriatal regionParkinson's disease patientsPutamenMotor severity scoresAssociated with increasesSubstantiaDATLongitudinal changesTremor scoreNegative associationNigraSubstantia nigra of Parkinson's disease patientsTremor severityPET biomarkersNoninvasive quantification of [18F]SynVesT-1 binding using simplified reference tissue model 2
Naganawa M, Gallezot J, Li S, Nabulsi N, Henry S, Cai Z, Matuskey D, Huang Y, Carson R. Noninvasive quantification of [18F]SynVesT-1 binding using simplified reference tissue model 2. European Journal Of Nuclear Medicine And Molecular Imaging 2024, 52: 113-121. PMID: 39155309, DOI: 10.1007/s00259-024-06885-6.Peer-Reviewed Original ResearchCitationsConceptsPositron emission tomographyCentrum semiovaleReference regionPositron emission tomography scanTest-retest variabilityTest-retest reproducibilitySynaptic vesicle glycoprotein 2AOne-tissue compartmentArterial blood samplesRetest scansGold standardBrain uptakeEmission tomographyBlood samplesCerebellumNoninvasive quantificationSRTM2ConclusionOur findingsPopulation averageHealthy participantsMetabolite analysisScan timeBPNDSemiovale
Get In Touch
Copy Link